Please note: The information displayed on this page might be outdated.
Unum Therapeutics Inc.: Unum Therapeutics is a clinical-stage biopharmaceutical company providing potentially curative T cell therapies to treat a broad range of cancer patients. Four product candidates currently in Phase I testing are based upon its novel Antibody-Coupled T cell Receptor (ACTR) therapy, a universal T cell that can be targeted using tumor-specific antibodies to attack different tumor types. Unum recently introduced a second technology called Bolt-On Chimeric Receptor (BOXR) to address immunosuppression in solid tumors and selected its first BOXR product candidate for preclinical development.
Based in...
US - New England
Public, USA
Market Cap
200 Cambridge Park Drive
Suite 3100
Cambridge, MA 02140
United States

Company Participants at Class of 2018 Biotech IPO Investor Day

  • Charles Wilson, President and CEO

Top 10 Holders of Unum Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Polar Capital LLP 73,335.29 2,500,000 0.00 Funds 9/30/20
BVF Partners LP 211.50 7,210 0.00 Stakes 9/10/20
Ridgeback Capital Management LP 100.00 3,409 0.00 Stakes 9/10/20
Fairmount Funds Management LLC 36.55 1,246 0.00 Stakes 9/10/20
Logos Global Management LP 1.72 5,682 0.00 Stakes 8/27/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.